Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Stenosis, Histiocytoma
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma
Interventions
REOLYSIN®
Biological
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
16 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
Interventions
Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab, Radiation Therapy
Procedure · Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Advanced and/or Metastatic Sarcoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
Interventions
doxorubicin HCl liposome
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Sarcoma, Malignant Fibrous Histiocytoma of the Bone, Chondrosarcoma of the Bone
Interventions
Endurance, Strengthening, Stretching, Home exercise program
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
celecoxib, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced May 21, 2026, 10:15 PM EDT
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced May 21, 2026, 10:15 PM EDT